What does the CJC-1295 + Ipamorelin blend do?
It pairs a GHRH-analogue (CJC-1295) with a ghrelin-mimetic (Ipamorelin) so both pituitary GH-releasing receptor systems are engaged simultaneously, producing greater GH release than either component alone.
Last reviewed 2026-07-13
Read the answer
The CJC-1295 + Ipamorelin blend is one of the most-used GH-secretagogue blends because it engages the two distinct receptor systems on pituitary somatotrophs simultaneously. CJC-1295 (typically the No DAC variant, which preserves pulsatile pharmacology) engages the growth-hormone-releasing-hormone receptor. Ipamorelin engages the growth-hormone-secretagogue receptor GHS-R1a, the same receptor as native ghrelin.
Because the two receptors trigger GH release through partially independent downstream pathways, engaging both simultaneously produces greater total GH release than engaging either alone at the same doses. This synergistic (rather than merely additive) effect is the pharmacological argument for combining them. Ipamorelin is preferred over older ghrelin-mimetics (GHRP-2, GHRP-6, Hexarelin) because it is selective for GH release without triggering the cortisol and prolactin elevations those older compounds produce.
In practical use, the blend is typically administered subcutaneously in the evening 1–2 hours after the last meal to avoid the blunting effect of high insulin and glucose on GHRH signalling. Cycling protocols vary; the general principle is that continuous high-dose exposure at any GHRH-active peptide can produce receptor desensitisation, so most grey-market protocols include planned breaks.
Blend-level clinical evidence for the specific CJC-1295 + Ipamorelin combination does not exist. The pharmacological logic is derived from component mechanisms.
Related on Healthy Mango
Related compounds
Related research blends
Related guides
Related comparisons
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone· Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · 2006
- Ipamorelin, the first selective growth hormone secretagogue· Raun K, Hansen BS, Johansen NL, et al. · 1998
Question
Related questions
Other questions that touch the same biology, evidence, or laboratory concepts.
What are GH secretagogues?
GH secretagogues are peptides that stimulate the pituitary to release growth hormone. They fall into two families: GHRH-analogues (Sermorelin, CJC-1295, Tesamorelin) and ghrelin-mimetics (Ipamorelin, older GHRPs).
What is the difference between CJC-1295 and CJC-1295 DAC?
The 'DAC' variant uses drug-affinity-complex chemistry that covalently binds to serum albumin, extending half-life from hours to about a week. The 'No DAC' variant retains the shorter half-life and pulsatile pharmacology.
What is Aura and why those three components?
Aura is a research blend of GHK-Cu + BPC-157 + KPV. It combines ECM remodelling (GHK-Cu), vascular supply (BPC-157), and inflammatory control (KPV). Chosen when inflammation-management is a priority.
When would you choose Aura vs Glow vs Klow?
Aura (GHK-Cu+BPC-157+KPV) when inflammation is the priority. Glow (GHK-Cu+BPC-157+TB-500) for skin rejuvenation and structural repair. Klow (all four) when every layer matters.